Duloxetine
Diabetic Neuropathies
Aga Khan UniversitySmall moleculePhase 4 / ApprovedActive
A
83/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 75/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Diabetic Neuropathies cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Capsaicin Corporacion Parc Tauli | Phase 4 | BBB |
Tapentadol Janssen Pharmaceutical K.K. | Phase 3 | BB |
Duloxetine Hydrochloride - Eli Lilly and Company | Phase 3 | BB |
FENTANYL Cephalon | Phase 3 | BB |
Mexiletine National Center for Research Resources (NCRR) | Phase 3 | BB |
View all 26 →
Same molecule, other indications
Duloxetine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →